SEC Form 3 · accession 0001193125-26-318054
Kalaris Therapeutics, Inc. · KLRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amy O'Leary Vandekop
Officer — See Remarks
Period of report
Jul 27, 2026
Accepted (ET)
Jul 27, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001754068
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 948 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.31 | holding | — | — | — | — | Apr 9, 2035 | Common Stock | 27,415 | — | D |
| Stock Option (right to buy)F2 | $6.81 | holding | — | — | — | — | Mar 18, 2036 | Common Stock | 20,000 | — | D |
Explanation of responses
- F1The option was granted on April 10, 2025. The shares underlying the option vested with respect to 25% of the shares on March 18, 2026 and the remainder are scheduled to vest in equal monthly installments through March 18, 2029.
- F2The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 19, 2027 and the remainder are scheduled to vest in equal monthly installments through March 19, 2030.
Remarks
Exhibit 24.1 - Power of Attorney Associate VP, Corporate Controller